May 15, 2006 | NEWS
May 15, 2006 deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics Companies to initiate work on molecular diagnostics for the risk of heart attack, type 2 diabetes and breast cancer Illumina to install large-scale genotyping system and...
May 7, 2006 | NEWS
May 7, 2006 Milestone in cancer genetics: a common genetic variant conferring significant risk of a common cancer in the general population Scientists at deCODE genetics (Nasdaq:DCGN) along with academic colleagues in Iceland, the US and Sweden today report the...
May 3, 2006 | NEWS
May 3, 2006 deCODE genetics (Nasdaq:DCGN) today announced that it has reached an agreement with the US Food and Drug Administration (FDA) on the design of its Phase III clinical trial for DG031, deCODE’s lead developmental compound for the prevention of heart attack....
Feb 21, 2006 | NEWS
February 21, 2006 deCODE genetics (Nasdaq:DCGN) today announced top-line results from Phase I clinical studies of DG041, the company’s developmental compound for the treatment of peripheral artery disease (PAD). The company has completed the Phase I studies of...
Jan 18, 2006 | NEWS
January 18, 2006 deCODE genetics (Nasdaq:DCGN) today announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS). The acquisition enables deCODE to broaden and enhance its cancer program by applying the company’s unique...
Jan 15, 2006 | NEWS
January 15, 2006 In a scientific paper published today a team of scientists from deCODE genetics (Nasdaq:DCGN) and colleagues report the discovery of a variant in a gene on chromosome 10 that represents the most significant genetic risk factor for type 2 diabetes...
